| CEO: | Adrian Kinkaid |
| Chairman: | Simon Gordon Douglas |
| Chief Scientific Officer: | Richard John Buick |
| Non-Executive Dir: | Colin Walsh, Matthew Baker |
| Address: | Springbank Industrial Estate, 1 Springbank Rd, Dunmurry, Belfast, United Kingdom, BT17 0QL |
| Website: | https://www.fusionantibodies.com/ |
| Sector: | Health Care(LSE) |
| Index: | FTSE AIM All-Share |
| ISIN: | GB00BDQZGK16 |
| Currency | UK Pounds |
| Share Price | 6.00p |
| Change Today | -0.45p |
| % Change | -6.98 % |
| 52 Week High | 19.25 |
| 52 Week Low | 5.50 |
| Volume | 897,525 |
| Shares Issued | 125.16m |
| Market Cap | £7.51m |
| RiskGrade | 464 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:13 | 20,000 @ 5.82p |
| 15:51 | 20,000 @ 5.82p |
| 14:20 | 30,000 @ 6.17p |
| 14:15 | 25,000 @ 6.00p |
| 14:15 | 600 @ 6.10p |
| Chair | Simon Gordon Douglas |
| CEO | Adrian Kinkaid |
You are here: research